Highlights Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
40.3 ^CHF	+0.12%		-1.10%	+14.16%

Apr. 09	Basilea Pharmaceutica Receives Grant for Antibiotics Program	MT
Apr. 04	Stocks Close in Green as Swiss Inflation Unexpectedly Slows	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Basilea Pharmaceutica Receives Grant for Antibiotics Program	Apr. 09	MT
Stocks Close in Green as Swiss Inflation Unexpectedly Slows	Apr. 04	MT
US FDA approves Basilea Pharmaceutica's antibiotic	Apr. 03	RE
US FDA approves Basilea Pharmaceutica's antibiotic	Apr. 03	RE
Continued strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	Mar. 11	DJ
Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2024	Feb. 13	CI
Basilea Pharmaceutica AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
Basilea Pharmaceutica Posts Lower FY23 Net Profit; Revenue Up	Feb. 13	MT
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	Feb. 13	DJ
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea	Feb. 08	MT
Cresemba(R) sales in Latin America trigger first sales milestone payment to Basilea	Jan. 19	DJ
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis	Jan. 15	MT
Basilea announces acquisition of preclinical antibiotics program from Spexis	Jan. 15	DJ
Basilea Pharmaceutica Eyes Commercialization Partner for Ceftobiprole Ahead of US FDA Verdict	Jan. 05	MT
Basilea to Get $1 Million Sales Milestone Payment from Pfizer for Antifungal Drug	Nov. 20	MT
Basilea Pharmaceutica Revises Revenue Guidance for the Full Year 2023	Nov. 13	CI
Basilea to Buy Investigational First-in-Class Antifungal Drug from Pfizer Affiliate	Nov. 13	MT
Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON	23-10-31	MT
Basilea Pharmaceutica to Buy Clinical-stage Antifungal Compound from Gravitas Therapeutics	23-10-19	MT
Basilea Pharmaceutica AG Provides Product Revenue Guidance for the Second Half of 2023	23-08-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Highlights

Filters